España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
KalVista Pharma
KALV
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$9.80
-0.65
-6.22%
At close: -
$9.84
0.04
0.41%
After Hours: 4:06 PM EDT
Get Report
Comment
KalVista Pharma (KALV) Forecast
News
Earnings
KalVista Pharma (KALV) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for KalVista Pharma (NASDAQ:KALV) Stock
KalVista Pharma Stock (NASDAQ: KALV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, November 04, 2024
KalVista Pharmaceuticals shares are trading h...
Benzinga Newsdesk
KalVista Pharmaceuticals Prices 5.5M Shares O...
Benzinga Newsdesk
Monday, October 28, 2024
KalVista Shares New Data on HAE Pill, Highlig...
Benzinga Newsdesk
Monday, October 07, 2024
HC Wainwright & Co. Reiterates Buy on KalVist...
Benzinga Newsdesk
Friday, October 04, 2024
KalVista Pharmaceuticals Presents New Data Sh...
Benzinga Newsdesk
Monday, September 30, 2024
Kalvista Pharmaceuticals Announced Marketing ...
Benzinga Newsdesk
Friday, September 27, 2024
KaiVista Pharmaceuticals shares are trading h...
Benzinga Newsdesk
Jones Trading Initiates Coverage On KalVista ...
Benzinga Newsdesk
Tuesday, September 10, 2024
KalVista Pharmaceuticals Announced That Brian...
Benzinga Newsdesk
Monday, September 09, 2024
Cantor Fitzgerald Reiterates Overweight on Ka...
Benzinga Newsdesk
Friday, September 06, 2024
HC Wainwright & Co. Reiterates Buy on KalVist...
Benzinga Newsdesk
KalVista Presented Additional Analyses Of Efficacy And Safety Of Sebetralstat From Phase 2 And Phase 3 Double-blind, Placebo-controlled Crossover Clinical Trials As Well As Interim Data From KONFIDENT-S, A Phase 3 Open-label Extension Trial
Nabaparna Bhattacharya
Needham Reiterates Buy on KalVista Pharma, Ma...
Benzinga Newsdesk
Thursday, September 05, 2024
KalVista Pharma Q1 2025 GAAP EPS $(0.87) Beat...
Benzinga Newsdesk
Tuesday, September 03, 2024
KalVista's Sebetralstat NDA Accepted by FDA, ...
Benzinga Newsdesk
Thursday, August 15, 2024
The European Medicines Agency Has Validated T...
Benzinga Newsdesk
Monday, July 15, 2024
HC Wainwright & Co. Reiterates Buy on KalVist...
Benzinga Newsdesk
Friday, July 12, 2024
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
Needham Maintains Buy on KalVista Pharma, Low...
Benzinga Newsdesk
Thursday, July 11, 2024
KalVista Submits FDA Application for Sebetral...
Benzinga Newsdesk
KalVista Pharma Q4 EPS $(1.02) Misses $(0.73)...
Benzinga Newsdesk
Thursday, June 27, 2024
KalVista Pharmaceuticals Has Initiated Open-L...
Benzinga Newsdesk
Tuesday, June 18, 2024
Needham Reiterates Buy on KalVista Pharma, Ma...
Benzinga Newsdesk
KalVista Submits New Drug Application For FDA...
Benzinga Newsdesk
Thursday, June 06, 2024
KalVista Pharmaceuticals Presented US Subgrou...
Benzinga Newsdesk
Monday, June 03, 2024
KalVista Highlights Real-World Data on HAE Tr...
Benzinga Newsdesk
Friday, May 31, 2024
KalVista Pharmaceuticals Presents Late-Breaki...
Benzinga Newsdesk
Friday, May 24, 2024
KalVista Pharmaceuticals Says That Ten Abstra...
Benzinga Newsdesk
Friday, May 03, 2024
HC Wainwright & Co. Maintains Buy on KalVista...
Benzinga Newsdesk
Wednesday, May 01, 2024
Needham Reiterates Buy on KalVista Pharma, Ma...
Benzinga Newsdesk
Kalvista Pharmaceuticals Announced Its Strate...
Benzinga Newsdesk
Thursday, April 11, 2024
Needham Reiterates Buy on KalVista Pharma, Ma...
Benzinga Newsdesk
Monday, March 18, 2024
KalVista Pharmaceuticals Presented Multiple A...
Benzinga Newsdesk
Tuesday, March 12, 2024
HC Wainwright & Co. Reiterates Buy on KalVist...
Benzinga Newsdesk
KalVista Pharmaceuticals Announced The UK Med...
Benzinga Newsdesk
Monday, March 11, 2024
Needham Maintains Buy on KalVista Pharma, Mai...
Benzinga Newsdesk
Recap: KalVista Pharma Q3 Earnings
Benzinga Insights
KalVista Pharma Q3 EPS $(0.84) Misses $(0.77)...
Benzinga Newsdesk
Friday, March 08, 2024
KalVista Pharmaceuticals Says It Will Present...
Benzinga Newsdesk
Thursday, March 07, 2024
KalVista Pharmaceuticals Announced That Benja...
Benzinga Newsdesk
Monday, February 26, 2024
KalVista Presents Additional Data On Its Phas...
Benzinga Newsdesk
Tuesday, February 20, 2024
KalVista Says UK MHRA Awarded Innovation Pass...
Benzinga Newsdesk
Friday, February 16, 2024
KalVista Pharmaceuticals Says It Will Present...
Benzinga Newsdesk
Thursday, February 15, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
KalVista Pharmaceuticals Has Priced The Publi...
Benzinga Newsdesk
Wednesday, February 14, 2024
KalVista Pharmaceuticals Announces Proposed P...
Benzinga Newsdesk
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
HC Wainwright & Co. Maintains Buy on KalVista...
Benzinga Newsdesk
Tuesday, February 13, 2024
Needham Maintains Buy on KalVista Pharma, Rai...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch